Trodelvy sacituzumab govitecan

Proactive premedication protocols shared peer-to-peer (Emend, Aloxi, Neulasta timing, 90-min infusion floor) are the single biggest differentiator between patients who persist on Trodelvy and those who abandon it after cycle 1.

• Trodelvy earns qualified loyalty from heavily pretreated patients who credit it with measurable tumor shrinkage or stability after Enhertu and other lines have failed, framing it as a genuine 'life-saver' despite harsh tolerability.
• Diarrhea and neutropenia dominate the lived-experience narrative, but patient-to-patient premedication sharing (loperamide timing, G-CSF self-injection, 90-minute infusion rule) meaningfully closes the gap between label guidance and real-world management.
• Hair loss is psychologically significant but normalized rapidly; the under-documented photosensitivity and heat sensitivity signal represents a dangerous blind spot that patients discover experientially rather than from their care teams.
• Cost, access navigation, and the absence of a biosimilar are emerging friction points as Trodelvy moves toward first-line TNBC use, creating a new patient-services intervention window before treatment even begins.